bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S4 from Pharmacological Inhibition of the Protein Kinase MRK/ZAK Radiosensitizes Medulloblastoma
Authors: Markowitz Daniel , Powell Caitlin , Tran Nhan L. , Berens Michael E. , Ryken Timothy C. , Vanan Magimairajan , Rosen Lisa , He Mingzhu , Sun Shan , Symons Marc , Al-Abed Yousef , Ruggieri Rosamaria
Published: April 2023

Animal weights during and after treatment. Color figure.
Supplementary Figure S3 from Pharmacological Inhibition of the Protein Kinase MRK/ZAK Radiosensitizes Medulloblastoma
Authors: Markowitz Daniel , Powell Caitlin , Tran Nhan L. , Berens Michael E. , Ryken Timothy C. , Vanan Magimairajan , Rosen Lisa , He Mingzhu , Sun Shan , Symons Marc , Al-Abed Yousef , Ruggieri Rosamaria
Published: April 2023

Radiosensitization of mammary carcinoma cells by M443.
Supplemental Figure 4 from Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma
Authors: Sinik Lenka , Minson Katherine A. , Tentler John J. , Carrico Jacqueline , Bagby Stacey M. , Robinson William A. , Kami Rotem , Burstyn-Cohen Tal , Eckhardt S. Gail , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , DeRyckere Deborah , Graham Douglas K.
Published: April 2023

Supplemental Figure 4 shows TAM-family kinase expression in melanoma cell lines.
Supplementary Figure S2 from Pharmacological Inhibition of the Protein Kinase MRK/ZAK Radiosensitizes Medulloblastoma
Authors: Markowitz Daniel , Powell Caitlin , Tran Nhan L. , Berens Michael E. , Ryken Timothy C. , Vanan Magimairajan , Rosen Lisa , He Mingzhu , Sun Shan , Symons Marc , Al-Abed Yousef , Ruggieri Rosamaria
Published: April 2023

Lack of radiosensitization of M443 on normal brain cells.
Supplementary Figure S1 from Pharmacological Inhibition of the Protein Kinase MRK/ZAK Radiosensitizes Medulloblastoma
Authors: Markowitz Daniel , Powell Caitlin , Tran Nhan L. , Berens Michael E. , Ryken Timothy C. , Vanan Magimairajan , Rosen Lisa , He Mingzhu , Sun Shan , Symons Marc , Al-Abed Yousef , Ruggieri Rosamaria
Published: April 2023

Synthesis of M443. Color figure.
Supplemental Figures from Epidermal Growth Factor Receptor (EGFR)-targeted Photoimmunotherapy (PIT) for the Treatment of EGFR-expressing Bladder Cancer
Authors: Railkar Reema , Krane L. Spencer , Li Q. Quentin , Sanford Thomas , Siddiqui Mohammad Rashid , Haines Diana , Vourganti Srinivas , Brancato Sam J. , Choyke Peter L. , Kobayashi Hisataka , Agarwal Piyush K.
Published: April 2023

Supplemental Figure 1: Expression of EGFR in cell lines; Supplemental Figure 2: In vitro analysis of pan IR700; Supplemental Figure 4: Pan IR700 based PIT induces cell death in 5637 cells; Supplemental Figure 5: Panitumumab or IR700 alone have no effects on bladder cancer cell lines; Supplemental Figure 7: Staurosporine induces early apoptosis in UMUC-5 cells; Supplemental Figure 8: Forward scatter and side scatter plots for PIT treated UMUC-5 cells 60 minutes post-NIR; Supplemental Figure 9: DCFDA assay to detect the generation of ROS in the presence and absence of pan IR700 PIT; Supplemental Figure 10: Tumor measurements of individual control and experimental mice; Supplemental Figure 11: Effect of pan IR700 based PIT on UMUC-3 xenograft
Supplementary Tables and Figures. from Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures
Authors: Kjær Ida , Lindsted Trine , Fröhlich Camilla , Olsen Jesper Velgaard , Horak Ivan David , Kragh Michael , Pedersen Mikkel Wandahl
Published: April 2023

Table S1 contains IC50 values for cetuximab inhibition, EGFR mutation and amplification status of tested cell lines. Figure S1 shows cetuximab binding to surface EGFR on HN5 and cetuximab resistant HN5 cell lines. Figure S2 shows EGFR levels in parental HN5 cells and cetuximab resistant clones. Figure S3 Overexposed image of immunoblot presented in Figure 2B. Figure S4 shows EGFR degradation upon treatment with anti-EGFR 2mixture for 48h. Figure S5 shows LNA-mediated knockdown of EGFR inhibit growth and proliferation of HN5, HN5 CR2, and HN5 CR14. Figure S6 EGFR levels in FaDu versus cetuximab resistant FaDu cell lines. Figure S7 HER3 and IGF1R plasticity as a mechanism of acquired cetuximab resistance in HN5 CR14. Figure S8 Full dose-response curves of cetuximab and EGFR+HER3+IGF1R 5 mixture in a panel of SCCUAT cell lines.
Supplemental Figure 6 from Epidermal Growth Factor Receptor (EGFR)-targeted Photoimmunotherapy (PIT) for the Treatment of EGFR-expressing Bladder Cancer
Authors: Railkar Reema , Krane L. Spencer , Li Q. Quentin , Sanford Thomas , Siddiqui Mohammad Rashid , Haines Diana , Vourganti Srinivas , Brancato Sam J. , Choyke Peter L. , Kobayashi Hisataka , Agarwal Piyush K.
Published: April 2023

Pan IR700 mediated PIT has no effect on normal urothelial cell line, UPS54.
Table S4 from JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines
Authors: Kani Kian , Garri Carolina , Tiemann Katrin , Malihi Paymaneh D. , Punj Vasu , Nguyen Anthony L. , Lee Janet , Hughes Lindsey D. , Alvarez Ruth M. , Wood Damien M. , Joo Ah Young , Katz Jonathan E. , Agus David B. , Mallick Parag
Published: April 2023

List of all EGFR pathway associated genes from RNA-seq
Table S3 from JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines
Authors: Kani Kian , Garri Carolina , Tiemann Katrin , Malihi Paymaneh D. , Punj Vasu , Nguyen Anthony L. , Lee Janet , Hughes Lindsey D. , Alvarez Ruth M. , Wood Damien M. , Joo Ah Young , Katz Jonathan E. , Agus David B. , Mallick Parag
Published: April 2023

Top 260 deferentially expressed genes in HCC827 and HCC827ZDR3
Table S1 from JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines
Authors: Kani Kian , Garri Carolina , Tiemann Katrin , Malihi Paymaneh D. , Punj Vasu , Nguyen Anthony L. , Lee Janet , Hughes Lindsey D. , Alvarez Ruth M. , Wood Damien M. , Joo Ah Young , Katz Jonathan E. , Agus David B. , Mallick Parag
Published: April 2023

Quantitative Proteomics Data
Table S1 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling
Authors: Puskás László G. , Mán Imola , Szebeni Gabor , Tiszlavicz László , Tsai Susan , James Michael A.
Published: April 2023

Clinical characteristics of CLPTM1L expression and survival study subjects
Figure S6 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling
Authors: Puskás László G. , Mán Imola , Szebeni Gabor , Tiszlavicz László , Tsai Susan , James Michael A.
Published: April 2023

Inhibition of MiaPaca tumorigenesis with purified anti-CLPTM1L and animal weight data
Figure S5 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling
Authors: Puskás László G. , Mán Imola , Szebeni Gabor , Tiszlavicz László , Tsai Susan , James Michael A.
Published: April 2023

Inhibition of tumor spheroid growth with anti-CLPTM1L
Supplementary Legends from Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylation
Authors: Samadder Pounami , Suchánková Tereza , Hylse Ondřej , Khirsariya Prashant , Nikulenkov Fedor , Drápela Stanislav , Straková Nicol , Vaňhara Petr , Vašíčková Kateřina , Kolářová Hana , Binó Lucia , Bittová Miroslava , Ovesná Petra , Kollár Peter , Fedr Radek , Ešner Milan , Jaroš Josef , Hampl Aleš , Krejčí Lumír , Paruch Kamil , Souček Karel
Published: April 2023

Supplementary Legends for Supplemetary Figure S1 - S11
Figure S4 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling
Authors: Puskás László G. , Mán Imola , Szebeni Gabor , Tiszlavicz László , Tsai Susan , James Michael A.
Published: April 2023

Inhibition of colony formation in select human cancer cell lines with anti-CLPTM1L
Supplementary Figures from Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylation
Authors: Samadder Pounami , Suchánková Tereza , Hylse Ondřej , Khirsariya Prashant , Nikulenkov Fedor , Drápela Stanislav , Straková Nicol , Vaňhara Petr , Vašíčková Kateřina , Kolářová Hana , Binó Lucia , Bittová Miroslava , Ovesná Petra , Kollár Peter , Fedr Radek , Ešner Milan , Jaroš Josef , Hampl Aleš , Krejčí Lumír , Paruch Kamil , Souček Karel
Published: April 2023

Figure S1. In vitro profiling of SCH900776 and its selected analogs. Figure S2. Analogs of MU380 with the N-trifluoromethylpyrazol pharmacophore. Figure S3. Dot plots of flow cytometric analysis using Î³H2AX and Annexin V staining related to Figure 2D. Figure S4. Dose response curves of relative viability of the tested cell lines treated with CHK1 inhibitors at indicated concentrations in combination with HU in the concentration range shown on the x-axis (related to Figure 3A). Figure S5. Dynamics of cytotoxic effects of CHK1 inhibitors alone and in combination with HU. Figure S6. Dose response curves of relative viability of the tested cell lines treated with CHK1 inhibitors at indicated concentration in combination with GEM in concentration range shown on the x-axis (related to Figure 3B). Figure S7. Dose response curves of relative viability of the tested cell lines treated with CHK1 inhibitors at indicated concentration in combination with irradiation in the dose range shown on the x-axis. Figure S8. Western blot analysis of total CHK1 and p-CHK1 (S296) levels in a panel of selected cell lines after indicated treatments. Figure S9. Drug retention analysis. Figure S10. MU380 induces CHK1 pS345 in mice hair follicles. Figure S11. Bioluminescent signal of SHO mice bearing MiaPaCa2 luc xenografts treated with GEM, SCH900776, or MU380 alone or in indicated combinations. Weight of MiaPaCa2 luc tumor-bearing animals. Representative images of Î³H2AX staining in MiaPaCa2 luc tumor sections.
Figure S2 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling
Authors: Puskás László G. , Mán Imola , Szebeni Gabor , Tiszlavicz László , Tsai Susan , James Michael A.
Published: April 2023

Monoclonal antibody epitope selection
Supplementary Figures S1-S7, Legends and Methods from Activating Transcription Factor 3 Expression as a Marker of Response to the Histone Deacetylase Inhibitor Pracinostat
Authors: Sooraj Dhanya , Xu Dakang , Cain Jason E. , Gold Daniel P. , Williams Bryan R.G.
Published: April 2023

Figure S1. Pracinostat reactivates acetylation of non-histone protein tubulin at higher doses. Figure S2. Alteration in malignant behavior of cancer cell lines in vitro with Pracinostat treatment. Figure S3. ATF3 regulates the transcriptional activation of RB1. Figure S4. Pracinostat treatment inhibits in vivo tumor growth. Figure S5. Pracinostat treatment inhibits the production of proangiogenic factor VEGF- A in vitro. Figure S6. ATF3 reactivation is crucial in determining the sensitivity of the HDACi treatment in bladder cancer. Figure S7. The level of expression of HDAC enzymes may dictate the degree of sensitivity in different cell lines in vitro. Supplementary Methods: Generation of stable knockdown cells; Quantitative RT-PCR.
Supplementary Figure 1 from TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors
Authors: Abo Muthana Al , Sasanuma Hiroyuki , Liu Xiaojun , Rajapakse Vinodh N. , Huang Shar-yin , Kiselev Evgeny , Takeda Shunichi , Plunkett William , Pommier Yves
Published: April 2023

Schematic representation of the strategy used to knockout TDP1 by CRISPR/Cas9 in TSCER2 (A) or HCT116 (B) cells. RT-PCR of TDP1 mRNA in TSCER2 is shown (A).
Supplementary Figures 1-5 from Targeting Interleukin-11 Receptor-α Impairs Human Endometrial Cancer Cell Proliferation and Invasion In Vitro and Reduces Tumor Growth and Metastasis In Vivo
Authors: Winship Amy L. , Van Sinderen Michelle , Donoghue Jacqueline , Rainczuk Kate , Dimitriadis Evdokia
Published: April 2023

Supplementary Figure 1. Ishikawa and HEC1A endometrial cancer cells secrete IL11 and express IL11Rα; Supplementary Figure 2. Targeting epithelial, but not stromal IL11Rα promtoes endometrial tumour apoptosis; Supplementary Figure 3. Anti-mouse IL11Rα neutralizing antibody does not reduce STAT3 activation in vitro; Supplementary Figure 4. IL11 inhibition did not reduce ERK activation in HEC1A endometrial tumours; Supplementary Figure 5. IL11 inhibition suppresses IL11 signalling components, but does not alter gene expression of other IL6 family cytokine members in HEC1A endometrial tumours
Supplementary Figures S1-S2 and Supplementary Tables S1-S3 from Identification of the Serine Biosynthesis Pathway as a Critical Component of BRAF Inhibitor Resistance of Melanoma, Pancreatic, and Non–Small Cell Lung Cancer Cells
Authors: Ross Kayleigh C. , Andrews Andrew J. , Marion Christopher D. , Yen Timothy J. , Bhattacharjee Vikram
Published: April 2023

Supplementary Table S1: Proteins upregulated follwoing vemurafenib treatment of SK-MEL-28VR1 cells. Supplementary Figure S1: PHGDH gene ablation of SK-MEL-28VR1 cells. Supplementary Figure S2: Gemcitabine induced sensitization of SK-MEL-28VR1 and BxPC3M1 cells to vemurafenib. Supplementary Table S2: Combination index values for gemcitabine+vemurafenib combination in SK-MEL-28VR1 cells. Supplementary Table S3: Combination index values for gemcitabine+vemurafenib combination in BxPC3M1 cells.
Supplementary Figure Legends and Supplementary Table 1 from Targeting Interleukin-11 Receptor-α Impairs Human Endometrial Cancer Cell Proliferation and Invasion In Vitro and Reduces Tumor Growth and Metastasis In Vivo
Authors: Winship Amy L. , Van Sinderen Michelle , Donoghue Jacqueline , Rainczuk Kate , Dimitriadis Evdokia
Published: April 2023

Supplementary Figure Legends 1-5 and Supplementary Table 1. Primer Sequences
Supplementary Methods. Supplementary Figures 1 through 8. Supplementary Tables 1 and 2. from Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia
Authors: Mu Chaofeng , Wu Xiaoyan , Ma Helen , Tao Wenjing , Zhang Guodong , Xia Xiaojun , Shen Jianliang , Mai Junhua , Sun Tong , Sun Xiaoping , Arlinghaus Ralph B. , Shen Haifa
Published: April 2023

Supplementary Methods. Supplementary Figure 1. 32Dp210T315I cells are resistant to dasatinib treatment. Supplementary Figure 2. Inhibition of Aurora B kinase activity with barasertib causes G2/M arrest and cell apoptosis. Supplementary Figure 3. Targeted TG101209 enriches in bone marrow. Supplementary Figure 4. TG101209 prevents cytokine-dependent resistance to ponatinib in 32Dp210T315I cells. Supplementary Figure 5. Treatment with targeted TG101209 significantly reduces leukemic cells in peripheral blood. Supplementary Figure 6. Treatment with imatinib and targeted TG101209 significantly extends survival of mice bearing p210WT leukemia. Supplementary Figure 7. TG101209 treatment has minimum impact on viability and colony formation ability of bone marrow cells. Supplementary Figure 8. TG101209 treatment effectively inhibits protein kinases in leukemia cells isolated from patients with blast crisis CML. Table S1. Characterization of untargeted and targeted TG101209 micelles. Table S2. Pharmacokinetic parameters of TG101209 formulations.
supplementary Figure S4 from The DNA-Binding Polyamine Moiety in the Vectorized DNA Topoisomerase II Inhibitor F14512 Alters Reparability of the Consequent Enzyme-Linked DNA Double-Strand Breaks
Authors: Bombarde Oriane , Larminat Florence , Gomez Dennis , Frit Philippe , Racca Carine , Gomes Bruno , Guilbaud Nicolas , Calsou Patrick
Published: April 2023

Figure S4 shows the calibration of the initial level of TOP2αcc after cell treatment with etoposide or F14512.
Figure S5 from Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor
Authors: Zeng Shan , Seifert Adrian M. , Zhang Jennifer Q. , Cavnar Michael J. , Kim Teresa S. , Balachandran Vinod P. , Santamaria-Barria Juan A. , Cohen Noah A. , Beckman Michael J. , Medina Benjamin D. , Rossi Ferdinand , Crawley Megan H. , Loo Jennifer K. , Maltbaek Joanna H. , Besmer Peter , Antonescu Cristina R. , DeMatteo Ronald P.
Published: April 2023

Supplementary Figure 5: the effect of imatinib on Wnt/Î²-catenin signaling in Kit^V558Î"/+ tumors
Figure S4 from Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor
Authors: Zeng Shan , Seifert Adrian M. , Zhang Jennifer Q. , Cavnar Michael J. , Kim Teresa S. , Balachandran Vinod P. , Santamaria-Barria Juan A. , Cohen Noah A. , Beckman Michael J. , Medina Benjamin D. , Rossi Ferdinand , Crawley Megan H. , Loo Jennifer K. , Maltbaek Joanna H. , Besmer Peter , Antonescu Cristina R. , DeMatteo Ronald P.
Published: April 2023

Figure S4. Cell viability assay (Dojindo) of murine HCC and B16 cells following 72h of treatment with PKF118-310 or vehicle (DMSO control).
Table S1 from The DNA-Binding Polyamine Moiety in the Vectorized DNA Topoisomerase II Inhibitor F14512 Alters Reparability of the Consequent Enzyme-Linked DNA Double-Strand Breaks
Authors: Bombarde Oriane , Larminat Florence , Gomez Dennis , Frit Philippe , Racca Carine , Gomes Bruno , Guilbaud Nicolas , Calsou Patrick
Published: April 2023

Supplementary Table S1
Figure S2 from Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor
Authors: Zeng Shan , Seifert Adrian M. , Zhang Jennifer Q. , Cavnar Michael J. , Kim Teresa S. , Balachandran Vinod P. , Santamaria-Barria Juan A. , Cohen Noah A. , Beckman Michael J. , Medina Benjamin D. , Rossi Ferdinand , Crawley Megan H. , Loo Jennifer K. , Maltbaek Joanna H. , Besmer Peter , Antonescu Cristina R. , DeMatteo Ronald P.
Published: April 2023

Figure S2. Murine model of metastatic GIST to the liver.
Supplementary Table S1 from Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab
Authors: Okazaki Satoshi , Loupakis Fotios , Stintzing Sebastian , Cao Shu , Zhang Wu , Yang Dongyun , Ning Yan , Sunakawa Yu , Stremitzer Stefan , Matsusaka Satoshi , Berger Martin D. , Parekh Anish , West Jordan D. , Miyamoto Yuji , Suenaga Mitsukuni , Schirripa Marta , Cremolini Chiara , Falcone Alfredo , Heinemann Volker , DePaolo R. William , Lenz Heinz-Josef
Published: April 2023

This table shows the association of each SNP and clinical outcome in TRIBE. The association between SNP and clinical outcome in FIRE-3 is also demonstrated when there are statistically significant associations in TRIBE.
Figure S1 from Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor
Authors: Zeng Shan , Seifert Adrian M. , Zhang Jennifer Q. , Cavnar Michael J. , Kim Teresa S. , Balachandran Vinod P. , Santamaria-Barria Juan A. , Cohen Noah A. , Beckman Michael J. , Medina Benjamin D. , Rossi Ferdinand , Crawley Megan H. , Loo Jennifer K. , Maltbaek Joanna H. , Besmer Peter , Antonescu Cristina R. , DeMatteo Ronald P.
Published: April 2023

Figure S1. The relative mRNA expression of DKK4 and CTNNB1 in human KIT+ cells.
Supplementary Figure S1 from Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab
Authors: Okazaki Satoshi , Loupakis Fotios , Stintzing Sebastian , Cao Shu , Zhang Wu , Yang Dongyun , Ning Yan , Sunakawa Yu , Stremitzer Stefan , Matsusaka Satoshi , Berger Martin D. , Parekh Anish , West Jordan D. , Miyamoto Yuji , Suenaga Mitsukuni , Schirripa Marta , Cremolini Chiara , Falcone Alfredo , Heinemann Volker , DePaolo R. William , Lenz Heinz-Josef
Published: April 2023

This figure shows the signal pathway of TLR1, TLR2, and TLR6. TLR1 and TLR6, each of which forms a heterodimer with TLR2, initiate MAPK or NFÎºB pathway through TAK1. MyD88: myeloid differentiation factor88, TRAF: TNF receptor-associated factor, IRAK: ã€€IL-1R associated kinase, TAK: TGFÎ²-activated kinase, TAB: TAK1-binding protein, MAPK: mitogen-activated protein kinase.
Supplementary Information Figure S3 from Dissecting Therapeutic Resistance to ERK Inhibition
Authors: Jha Sharda , Morris Erick J. , Hruza Alan , Mansueto My Sam , Schroeder Gottfried K. , Arbanas Jaren , McMasters Daniel , Restaino Clifford R. , Dayananth Priya , Black Stuart , Elsen Nathaniel L. , Mannarino Anthony , Cooper Alan , Fawell Stephen , Zawel Leigh , Jayaraman Lata , Samatar Ahmed A.
Published: April 2023

HTRF and Biacore binding data for active and inactive ERK1 in the presence of SCH772984
Supplementary Figure S4 from Dual Inhibition of NOX2 and Receptor Tyrosine Kinase by BJ-1301 Enhances Anticancer Therapy Efficacy via Suppression of Autocrine-Stimulatory Factors in Lung Cancer
Authors: Gautam Jaya , Ku Jin-Mo , Regmi Sushil Chandra , Jeong Hyunyoung , Wang Ying , Banskota Suhrid , Park Myo-Hyeon , Nam Tae-gyu , Jeong Byeong-Seon , Kim Jung-Ae
Published: April 2023

Differential expression of NOX homologs in A549 and H1299 human lung cancer cells. A, Quantitative analysis of mRNA extracted from the two cancer cell lines and positive control cell lines was performed using ABI PCR primers and Quantitect PCR probe mix. Caco2 and HT29 cell lines were used for NOX1, DU145 for NOX2, p67phox and p47phox, and HUVEC for NOX4. *P<0.05 versus positive control group. #P<0.05 versus A549 cells. B, mRNA copy number of NOX1, NOX2 and NOX4 was determined in A549 and H1299 lung cancer cells.
Supplementary Information Figure S2 from Dissecting Therapeutic Resistance to ERK Inhibition
Authors: Jha Sharda , Morris Erick J. , Hruza Alan , Mansueto My Sam , Schroeder Gottfried K. , Arbanas Jaren , McMasters Daniel , Restaino Clifford R. , Dayananth Priya , Black Stuart , Elsen Nathaniel L. , Mannarino Anthony , Cooper Alan , Fawell Stephen , Zawel Leigh , Jayaraman Lata , Samatar Ahmed A.
Published: April 2023

Maximal Velocity and Km values
Supplementary Figure S2 from Dual Inhibition of NOX2 and Receptor Tyrosine Kinase by BJ-1301 Enhances Anticancer Therapy Efficacy via Suppression of Autocrine-Stimulatory Factors in Lung Cancer
Authors: Gautam Jaya , Ku Jin-Mo , Regmi Sushil Chandra , Jeong Hyunyoung , Wang Ying , Banskota Suhrid , Park Myo-Hyeon , Nam Tae-gyu , Jeong Byeong-Seon , Kim Jung-Ae
Published: April 2023

No change in intracellular signalling pathways and ROS production by BJ-1301 alone treatment. HUVECs were treated with indicated concentration of BJ-1301. Protein extracts were examined for phosphorylation of MAPKs (A) and NF-kB nuclear translocation (B). ROS production (C) was measured by using an inverted fluorescent microscope (TE2000-U; Nikon, Japan).
Supplementary Information Figure S1 from Dissecting Therapeutic Resistance to ERK Inhibition
Authors: Jha Sharda , Morris Erick J. , Hruza Alan , Mansueto My Sam , Schroeder Gottfried K. , Arbanas Jaren , McMasters Daniel , Restaino Clifford R. , Dayananth Priya , Black Stuart , Elsen Nathaniel L. , Mannarino Anthony , Cooper Alan , Fawell Stephen , Zawel Leigh , Jayaraman Lata , Samatar Ahmed A.
Published: April 2023

Sequencing of HCT116 resistant (HCT116R) cell lines
Supplementary Fig. S3 from Dual Inhibition of NOX2 and Receptor Tyrosine Kinase by BJ-1301 Enhances Anticancer Therapy Efficacy via Suppression of Autocrine-Stimulatory Factors in Lung Cancer
Authors: Gautam Jaya , Ku Jin-Mo , Regmi Sushil Chandra , Jeong Hyunyoung , Wang Ying , Banskota Suhrid , Park Myo-Hyeon , Nam Tae-gyu , Jeong Byeong-Seon , Kim Jung-Ae
Published: April 2023

Specific actions of VEGF and BJ-1301 in NOX2 protein expression. Protein extracts from HUVECs treated with indicated concentration of BJ-1301 were loaded on SDS PAGE together with His-tagged human NOX1 (NOX1-1359H, Creative Biomart, NY, USA ), His+T7-tagged human NOX2 (LSG25251, LifeSpan Biosciences, WA, USA), and GST-tagged human NOX-4 (NOX4-1336H, Creative Biomart, NY, USA) recombinant proteins. Each isoform of NOX proteins was detected by using anti-NOX1 (ab55831, Abcam, MA, USA), anti-NOX2 (ab129068, Abcam, MA, USA), or anti-NOX4 (ab109225, Abcam, MA, USA) antibody. The membranes were reprobed to get the immunoblot of His, T7 or GST protein using anti-His (A00186100, Genscript, NJ, USA), anti-T7 (ab97964, Abcam, MA, USA), or anti-GST (ab19256, Abcam, MA, USA) antibody, respectively.
Supplementary methods, legends, Figures S1-S5, and Tables S1-S2 from Inhibition of Megakaryocyte Differentiation by Antibody–Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia
Authors: Zhao Hui , Gulesserian Sara , Ganesan Sathish Kumar , Ou Jimmy , Morrison Karen , Zeng Zhilan , Robles Veronica , Snyder Josh , Do Lisa , Aviña Hector , Karki Sher , Stover David R. , Doñate Fernando
Published: April 2023

Fig. S1. Structure of AGS-16C3F; Figure S2. ENPP3 was not expressed in megakaryocytes; Figure S3. AGS-16C3F did not affect platelet activation; Figure S4. Maturing MKs did not express ENPP3; Figure S5. Fc blocker inhibited FcγRIIA pathway in tumor cells; Table S1. Information about ADCs used in this study; Table S2. Quantitative binding assessment of Fc blockers to human FcγRs
Supplementary Figure2 from BRD4 Regulates EZH2 Transcription through Upregulation of C-MYC and Represents a Novel Therapeutic Target in Bladder Cancer
Authors: Wu Xinchao , Liu Dong , Tao Dan , Xiang Wei , Xiao Xingyuan , Wang Miao , Wang Liang , Luo Gang , Li Yawei , Zeng Fuqing , Jiang Guosong
Published: April 2023

Vector backbone of EZH2 and C-MYC expression plasmids
Supplementary Figure S3 from Enzymatic Inactivation of Endogenous IgG by IdeS Enhances Therapeutic Antibody Efficacy
Authors: Järnum Sofia , Runström Anna , Bockermann Robert , Winstedt Lena , Crispin Max , Kjellman Christian
Published: April 2023

Human IgG concentration in mouse serum after a single i.p. administration of 1 g/kg IVIg in SCID mice.
Supplementary Figure1 from BRD4 Regulates EZH2 Transcription through Upregulation of C-MYC and Represents a Novel Therapeutic Target in Bladder Cancer
Authors: Wu Xinchao , Liu Dong , Tao Dan , Xiang Wei , Xiao Xingyuan , Wang Miao , Wang Liang , Luo Gang , Li Yawei , Zeng Fuqing , Jiang Guosong
Published: April 2023

Vector backbone of BRD4, C-MYC and EZH2 ShRNAs
Supplementary Figure S1 from Enzymatic Inactivation of Endogenous IgG by IdeS Enhances Therapeutic Antibody Efficacy
Authors: Järnum Sofia , Runström Anna , Bockermann Robert , Winstedt Lena , Crispin Max , Kjellman Christian
Published: April 2023

SDS-PAGE separation of plasma treated with 10 Ãƒâ€šÃ,âµg/mL IdeS
Figure S1 from Herpes Simplex Virus Glycoprotein D Targets a Specific Dendritic Cell Subset and Improves the Performance of Vaccines to Human Papillomavirus-Associated Tumors
Authors: Porchia Bruna F.M.M. , Moreno Ana Carolina R. , Ramos Rodrigo N. , Diniz Mariana O. , de Andrade Laís Helena T.M. , Rosa Daniela S. , Barbuto José Alexandre M. , Boscardin Silvia B. , Ferreira Luís Carlos S.
Published: April 2023

Figure S1. Immunization with gDE7 admixed with poly (I:C) induces full therapeutic antitumor protection in WT, TLR4 KO and CD4+ T cells KO mice.
Supplementary Table 2 from MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2
Authors: Li Peilong , Zhang Xin , Wang Haiyan , Wang Lili , Liu Tong , Du Lutao , Yang Yongmei , Wang Chuanxin
Published: April 2023

Supplementary Table 2 Association of MALAT1 expression with clinical parameters in CRC patients
Supplemental Table 2 from Bortezomib Inhibits Giant Cell Tumor of Bone through Induction of Cell Apoptosis and Inhibition of Osteoclast Recruitment, Giant Cell Formation, and Bone Resorption
Authors: Xu Leqin , Luo Jian , Jin Rongrong , Yue Zhiying , Sun Peng , Yang Zhengfeng , Yang Xinghai , Wan Wei , Zhang Jishen , Li Shichang , Liu Mingyao , Xiao Jianru
Published: April 2023

The sequences of primers used in this study
Supplementary Figure 5 from MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2
Authors: Li Peilong , Zhang Xin , Wang Haiyan , Wang Lili , Liu Tong , Du Lutao , Yang Yongmei , Wang Chuanxin
Published: April 2023

Supplementary Figure 5. The invasive cells per field in Figure 5G was quantified. *, P<0.05.
Supplemental Figure legend from Bortezomib Inhibits Giant Cell Tumor of Bone through Induction of Cell Apoptosis and Inhibition of Osteoclast Recruitment, Giant Cell Formation, and Bone Resorption
Authors: Xu Leqin , Luo Jian , Jin Rongrong , Yue Zhiying , Sun Peng , Yang Zhengfeng , Yang Xinghai , Wan Wei , Zhang Jishen , Li Shichang , Liu Mingyao , Xiao Jianru
Published: April 2023

Supplemental Figure legend
Supplementary Figure 4 from MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2
Authors: Li Peilong , Zhang Xin , Wang Haiyan , Wang Lili , Liu Tong , Du Lutao , Yang Yongmei , Wang Chuanxin
Published: April 2023

Supplementary Figure 4. SW480 and SW620 cells were transfected with si-EZH2 for 48 hours, and then the EZH2 mRNA level (A) and protein level (B) were detected by using RT-qPCR and Western blot method, respectively. **, P<0.01;***,P<0.001.
Supplementary Data Tables 1-3 from Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology
Authors: Yu Jia Xin , Craig Amanda J. , Duffy Mary E. , Villacorta-Martin Carlos , Miguela Verónica , Ruiz de Galarreta Marina , Scopton Alexander P. , Silber Lisa , Maldonado Andres Y. , Rialdi Alexander , Guccione Ernesto , Lujambio Amaia , Villanueva Augusto , Dar Arvin C.
Published: April 2023

Supplemental Table 1 shows RNA-seq signature genes. Supplementary Table 2 shows mass spectrometry profiling data for AD80 in HUH7. Supplementary Table 3 shows in vitro profiling data on compounds.
Figure S1-S5 from Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1–Stat3
Authors: Wu Chuan Xing , Xu Aimin , Zhang Cathy C. , Olson Peter , Chen Lin , Lee Terence K. , Cheung Tan To , Lo Chung Mau , Wang Xiao Qi
Published: April 2023

Figure S1. PF-03084014 selective inhibits high Notch1 expression HCC cells and does not suppress normal hepatocytes proliferation; Figure S2. Intermittent dosing of PF-03084014 reduced gastrointestinal toxicity; Figure S3. Antitumor effect of PF-03084014 on HCC monolayer cell derived orthotopic tumor; Figure S4. Pretreatment with PF-03084014 in vitro decreased HCC sphere's tumorigenicity in vivo; Figure S5. PF-03084014 inhibits mRNA levels of Notch1, HEY1 and Dll1. mRNA levels of Notch1, HEY1, and DLL1 in 97H spheres treated with PF-03084014 versus DMSO.
Supplementary Table S6 from Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017
Authors: Uitdehaag Joost C.M. , Kooijman Jeffrey J. , de Roos Jeroen A.D.M. , Prinsen Martine B.W. , Dylus Jelle , Willemsen-Seegers Nicole , Kawase Yusuke , Sawa Masaaki , de Man Jos , van Gerwen Suzanne J.C. , Buijsman Rogier C. , Zaman Guido J.R.
Published: April 2023

Sensitivity and specificity of drug response markers
Supplementary Table S3 from Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017
Authors: Uitdehaag Joost C.M. , Kooijman Jeffrey J. , de Roos Jeroen A.D.M. , Prinsen Martine B.W. , Dylus Jelle , Willemsen-Seegers Nicole , Kawase Yusuke , Sawa Masaaki , de Man Jos , van Gerwen Suzanne J.C. , Buijsman Rogier C. , Zaman Guido J.R.
Published: April 2023

Cell panel data
Supplementary Table S1 from Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017
Authors: Uitdehaag Joost C.M. , Kooijman Jeffrey J. , de Roos Jeroen A.D.M. , Prinsen Martine B.W. , Dylus Jelle , Willemsen-Seegers Nicole , Kawase Yusuke , Sawa Masaaki , de Man Jos , van Gerwen Suzanne J.C. , Buijsman Rogier C. , Zaman Guido J.R.
Published: April 2023

Chemical structures and suppliers of compounds used in study
Supplementary Figure S6 from Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017
Authors: Uitdehaag Joost C.M. , Kooijman Jeffrey J. , de Roos Jeroen A.D.M. , Prinsen Martine B.W. , Dylus Jelle , Willemsen-Seegers Nicole , Kawase Yusuke , Sawa Masaaki , de Man Jos , van Gerwen Suzanne J.C. , Buijsman Rogier C. , Zaman Guido J.R.
Published: April 2023

Waterfall plots of the VEGFR inhibitors
Supplementary Figure S5 from Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017
Authors: Uitdehaag Joost C.M. , Kooijman Jeffrey J. , de Roos Jeroen A.D.M. , Prinsen Martine B.W. , Dylus Jelle , Willemsen-Seegers Nicole , Kawase Yusuke , Sawa Masaaki , de Man Jos , van Gerwen Suzanne J.C. , Buijsman Rogier C. , Zaman Guido J.R.
Published: April 2023

Analysis of MEK and BRAF inhibitors approved before Nov. 2013 in a 102 cell line profiling
Supplementary Figure S4 from Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017
Authors: Uitdehaag Joost C.M. , Kooijman Jeffrey J. , de Roos Jeroen A.D.M. , Prinsen Martine B.W. , Dylus Jelle , Willemsen-Seegers Nicole , Kawase Yusuke , Sawa Masaaki , de Man Jos , van Gerwen Suzanne J.C. , Buijsman Rogier C. , Zaman Guido J.R.
Published: April 2023

Analysis of EGFR and HER2 inhibitors approved before Nov. 2013 in a 102 cell line profiling
Table S2 from Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma
Authors: Krasniqi Ahmet , D'Huyvetter Matthias , Xavier Catarina , Van der Jeught Kevin , Muyldermans Serge , Van Der Heyden José , Lahoutte Tony , Tavernier Jan , Devoogdt Nick
Published: April 2023

Ex vivo biodistribution of 14 anti-hCD20 sdAbs and non-target control sdAb (ctrl sdAb), radiolabeled with 99mTc, in Daudi. Results are expressed as % IA/g {plus minus} SD (n = 3 per SdAb). T/M: Tumor-to-Muscle ratio; T/B: Tumor-to-Blood ratio.
Figure S5 from ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms
Authors: Couts Kasey L. , Bemis Judson , Turner Jacqueline A. , Bagby Stacey M. , Murphy Danielle , Christiansen Jason , Hintzsche Jennifer D. , Le Anh , Pitts Todd M. , Wells Keith , Applegate Allison , Amato Carol , Multani Pratik , Chow-Maneval Edna , Tentler John J. , Shellman Yiqun G. , Rioth Matthew J. , Tan Aik-Choon , Gonzalez Rene , Medina Theresa , Doebele Robert C. , Robinson William A.
Published: April 2023

Additional ALK inhibitor testing and IC50 values
Figure S3 from ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms
Authors: Couts Kasey L. , Bemis Judson , Turner Jacqueline A. , Bagby Stacey M. , Murphy Danielle , Christiansen Jason , Hintzsche Jennifer D. , Le Anh , Pitts Todd M. , Wells Keith , Applegate Allison , Amato Carol , Multani Pratik , Chow-Maneval Edna , Tentler John J. , Shellman Yiqun G. , Rioth Matthew J. , Tan Aik-Choon , Gonzalez Rene , Medina Theresa , Doebele Robert C. , Robinson William A.
Published: April 2023

Non-specific immunoblot bands in MB 1692 and MB 1374
Figure S1 from ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms
Authors: Couts Kasey L. , Bemis Judson , Turner Jacqueline A. , Bagby Stacey M. , Murphy Danielle , Christiansen Jason , Hintzsche Jennifer D. , Le Anh , Pitts Todd M. , Wells Keith , Applegate Allison , Amato Carol , Multani Pratik , Chow-Maneval Edna , Tentler John J. , Shellman Yiqun G. , Rioth Matthew J. , Tan Aik-Choon , Gonzalez Rene , Medina Theresa , Doebele Robert C. , Robinson William A.
Published: April 2023

ALK qRT-PCR screen in melanoma PDX models
Supplementary Table S4 from Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor
Authors: Langdon Casey G. , Platt James T. , Means Robert E. , Iyidogan Pinar , Mamillapalli Ramanaiah , Klein Michael , Held Matthew A. , Lee Jong Woo , Koo Ja Seok , Hatzis Christos , Hochster Howard S. , Stern David F.
Published: April 2023

Contribution of agents to filtered combinations
Supplementary Table S2 from Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor
Authors: Langdon Casey G. , Platt James T. , Means Robert E. , Iyidogan Pinar , Mamillapalli Ramanaiah , Klein Michael , Held Matthew A. , Lee Jong Woo , Koo Ja Seok , Hatzis Christos , Hochster Howard S. , Stern David F.
Published: April 2023

Single agent AUC
supplemental tables and figures from Risk of Pneumonitis Associated with Programmed Cell Death 1 Inhibitors in Cancer Patients: A Meta-analysis
Authors: Zhang Sheng , Liang Fei , Zhu Ji , Chen Qiang
Published: April 2023

supplemental tables and figures
Supplementary Table S1 from Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor
Authors: Langdon Casey G. , Platt James T. , Means Robert E. , Iyidogan Pinar , Mamillapalli Ramanaiah , Klein Michael , Held Matthew A. , Lee Jong Woo , Koo Ja Seok , Hatzis Christos , Hochster Howard S. , Stern David F.
Published: April 2023

Agents, targets and target categories
Supplementary Figure S4 from Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide–Generating Agents Improves the Therapeutic Effects of Nanomedicines
Authors: Islam Waliul , Fang Jun , Imamura Takahisa , Etrych Tomas , Subr Vladimir , Ulbrich Karel , Maeda Hiroshi
Published: April 2023

Supplementary Figure S4 shows the AOM/DSS induced colon tumor nodules after treatment with P-THP and rhodamine-BSA conjugate (fluorescent image).
Supplementary Figure S2 from Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide–Generating Agents Improves the Therapeutic Effects of Nanomedicines
Authors: Islam Waliul , Fang Jun , Imamura Takahisa , Etrych Tomas , Subr Vladimir , Ulbrich Karel , Maeda Hiroshi
Published: April 2023

Supplementary Figure S2 shows increased survival of B16 melanoma treated with combination of polymeric drug (P-THP) and various NO donors.
Supplementary Figure S2 from Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor
Authors: Langdon Casey G. , Platt James T. , Means Robert E. , Iyidogan Pinar , Mamillapalli Ramanaiah , Klein Michael , Held Matthew A. , Lee Jong Woo , Koo Ja Seok , Hatzis Christos , Hochster Howard S. , Stern David F.
Published: April 2023

Heatmap of hierarchical clustering of normalized AUC and hierarchical clustering of cell lines
Supplementary Table 1 from Necuparanib, A Multitargeting Heparan Sulfate Mimetic, Targets Tumor and Stromal Compartments in Pancreatic Cancer
Authors: MacDonald Amanda , Priess Michelle , Curran Jennifer , Guess Jamey , Farutin Victor , Oosterom Ilse , Chu Chia Lin , Cochran Edward , Zhang Lynn , Getchell Kristen , Lolkema Martijn , Schultes Birgit C. , Krause Silva
Published: April 2023

Supplementary Table 1 lists proteins significantly altered by necuparanib treatment
Supplemental Figure 1 from Necuparanib, A Multitargeting Heparan Sulfate Mimetic, Targets Tumor and Stromal Compartments in Pancreatic Cancer
Authors: MacDonald Amanda , Priess Michelle , Curran Jennifer , Guess Jamey , Farutin Victor , Oosterom Ilse , Chu Chia Lin , Cochran Edward , Zhang Lynn , Getchell Kristen , Lolkema Martijn , Schultes Birgit C. , Krause Silva
Published: April 2023

Supplemental Figure 1 shows Pancreatic stellate cells (PSCs) promoted tumor cell invasion through close cell-cell interactions.
Supplementary Figure 1 from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers
Authors: Chen Luxi , Yuan Yi , Kar Shreya , Kanchi Madhu M. , Arora Suruchi , Kim Ji E. , Koh Pei F. , Yousef Einas , Samy Ramar P. , Shanmugam Muthu K. , Tan Tuan Z. , Shin Sung W. , Arfuso Frank , Shen Han M. , Yang Henry , Goh Boon C. , Park Joo I. , Gaboury Louis , Lobie Peter E. , Sethi Gautam , Lim Lina H.K. , Kumar Alan P.
Published: April 2023

Supplementary Figure 1: High ANXA1 and PPARγ expression levels positively correlates with the invasive, high-grade phenotype
Supplemental Figure 3 from Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy
Authors: Tyler Paul M. , Servos Mariah M. , de Vries Romy C. , Klebanov Boris , Kashyap Trinayan , Sacham Sharon , Landesman Yosef , Dougan Michael , Dougan Stephanie K.
Published: April 2023

Supplemental Figure 3: Degranulation of effector CD8 T cells is affected by selinexor.
Supplementary Materials & Methods from Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death
Authors: Asthana Abhishek , Ramakrishnan Parameswaran , Vicioso Yorleny , Zhang Keman , Parameswaran Reshmi
Published: April 2023

Supplementary Materials & Methods
Figure S6 from Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death
Authors: Asthana Abhishek , Ramakrishnan Parameswaran , Vicioso Yorleny , Zhang Keman , Parameswaran Reshmi
Published: April 2023

Hematological profile after In vivo DON administration.
Table S2 from Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice
Authors: Wang Rong , Yamada Tadaaki , Arai Sachiko , Fukuda Koji , Taniguchi Hirokazu , Tanimoto Azusa , Nishiyama Akihiro , Takeuchi Shinji , Yamashita Kaname , Ohtsubo Koshiro , Matsui Junji , Onoda Naoyoshi , Hirata Eishu , Taira Shu , Yano Seiji
Published: April 2023

Supplementary Table 2 shows the production of angiogenesis-related cytokines in the supernatant of ATC cells.
Table S1 from Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice
Authors: Wang Rong , Yamada Tadaaki , Arai Sachiko , Fukuda Koji , Taniguchi Hirokazu , Tanimoto Azusa , Nishiyama Akihiro , Takeuchi Shinji , Yamashita Kaname , Ohtsubo Koshiro , Matsui Junji , Onoda Naoyoshi , Hirata Eishu , Taira Shu , Yano Seiji
Published: April 2023

Supplementary Table 1 shows summary of the sample sizes
Figure S4 from Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death
Authors: Asthana Abhishek , Ramakrishnan Parameswaran , Vicioso Yorleny , Zhang Keman , Parameswaran Reshmi
Published: April 2023

siRNA mediated OGT silencing reduces proliferation and induce apoptosis.
Figure S6 from Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice
Authors: Wang Rong , Yamada Tadaaki , Arai Sachiko , Fukuda Koji , Taniguchi Hirokazu , Tanimoto Azusa , Nishiyama Akihiro , Takeuchi Shinji , Yamashita Kaname , Ohtsubo Koshiro , Matsui Junji , Onoda Naoyoshi , Hirata Eishu , Taira Shu , Yano Seiji
Published: April 2023

Supplementary Figure 6 shows vessel density in the brain or subcutaneuos tumors of OCUT-1C cells treated with lenvatinib or sorafenib for 3 days.
Figure S2 from Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death
Authors: Asthana Abhishek , Ramakrishnan Parameswaran , Vicioso Yorleny , Zhang Keman , Parameswaran Reshmi
Published: April 2023

DON reduces proliferation and induces apoptosis.
Figure S1 from Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice
Authors: Wang Rong , Yamada Tadaaki , Arai Sachiko , Fukuda Koji , Taniguchi Hirokazu , Tanimoto Azusa , Nishiyama Akihiro , Takeuchi Shinji , Yamashita Kaname , Ohtsubo Koshiro , Matsui Junji , Onoda Naoyoshi , Hirata Eishu , Taira Shu , Yano Seiji
Published: April 2023

Supplementary Figure 1 shows the effect of lenvatinib and sorafenib on the viability of human anaplastic thyroid cancer cells in 3D-culture plates in vitro.
Table S2 from Mechanism-informed Repurposing of Minocycline Overcomes Resistance to Topoisomerase Inhibition for Peritoneal Carcinomatosis
Authors: Huang Huang-Chiao , Liu Joyce , Baglo Yan , Rizvi Imran , Anbil Sriram , Pigula Michael , Hasan Tayyaba
Published: April 2023

Comparison of minocycline and irinotecan doses used in this study versus in the clinic.
Table S1 from Mechanism-informed Repurposing of Minocycline Overcomes Resistance to Topoisomerase Inhibition for Peritoneal Carcinomatosis
Authors: Huang Huang-Chiao , Liu Joyce , Baglo Yan , Rizvi Imran , Anbil Sriram , Pigula Michael , Hasan Tayyaba
Published: April 2023

Physical characterizations of nanoliposomal irinotecan (nal-IRI) for in vivo study.
Supplementary Figure S1 from Oxaliplatin–DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy
Authors: Zimmermann Maike , Li Tao , Semrad Thomas J. , Wu Chun-Yi , Yu Aiming , Cimino George , Malfatti Michael , Haack Kurt , Turteltaub Kenneth W. , Pan Chong-xian , Cho May , Kim Edward J. , Henderson Paul T.
Published: April 2023

Supplementary Figure S1 showing correlation between CRC cell line oxaliplatin sensitivity and oxaliplatin-DNA area under the adduct curve
Figure S1 from Mechanism-informed Repurposing of Minocycline Overcomes Resistance to Topoisomerase Inhibition for Peritoneal Carcinomatosis
Authors: Huang Huang-Chiao , Liu Joyce , Baglo Yan , Rizvi Imran , Anbil Sriram , Pigula Michael , Hasan Tayyaba
Published: April 2023

Platinum-resistant human epithelial ovarian cancer cell lines OVCAR-5 and OVCAR-4 expresses tyrosyl-DNA phosphodiesterase 1 (Tdp1). The Tdp1 protein expression levels in human epithelial ovarian carcinoma cell lines OVCAR-5 (derived from the ascitic fluid of EOC patient without prior treatment; tumor characterized to be platinum-resistant) and OVCAR-4 (derived from the ascitic fluid of platinum-refractory EOC patient) were evaluated by Western Blot. Tdp1 expression was found higher in the OVCAR-4 cells compared to that in the OVCAR-5 cells.
Table S2 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
Authors: Wang Ruizhong , Bhat-Nakshatri Poornima , Padua Maria B. , Prasad Mayuri S , Anjanappa Manjushree , Jacobson Max , Finnearty Courtney , Sefcsik Victoria , McElyea Kyle , Redmond Rachael , Sandusky George , Penthala Narsimha , Crooks Peter A , Liu Jianguo , Zimmers Teresa , Nakshatri Harikrishna
Published: April 2023

Results of myogenesis and myopathy pathway analyses of skeletal muscle
Table S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
Authors: Wang Ruizhong , Bhat-Nakshatri Poornima , Padua Maria B. , Prasad Mayuri S , Anjanappa Manjushree , Jacobson Max , Finnearty Courtney , Sefcsik Victoria , McElyea Kyle , Redmond Rachael , Sandusky George , Penthala Narsimha , Crooks Peter A , Liu Jianguo , Zimmers Teresa , Nakshatri Harikrishna
Published: April 2023

Tumor incidence and growth patterns in PyMT+ mice with and without DMAPT treatment